Novo Nordisk's Ozempic

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

CNBC - 1d

Novo Nordisk shares fall on latest trial results for new obesity drug

Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema

Financial Times - 1d

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

ABC News - 6d

Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests

Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom received a warning letter from FDA.

CNBC - 6h

Hikma races to launch generic versions of blockbuster obesity drugs

Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year

Financial Times - 2d

Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

MarketWatch - 1d

Nathy Peluso has found her musical language

The Latin Grammy-winning Argentine singer behind the album "Grasa" spoke to De Los ahead of her March 15 show at the Novo.

Los Angeles Times - 5h

Latest in Novo Nordisk's Ozempic